| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
CLINICAL REVIEW |
Diabetes Research Institute, Norfolk, Virginia 23510
Address all correspondence and requests for reprints to: Dr. Aaron Vinik, Diabetes Research Institute, 855 West Brambleton Avenue, Norfolk, Virginia 23510. E-mail: vinikal{at}evmsmail.evms.edu.
Context: Up to 25% of individuals with diabetes develop painful diabetic neuropathy, suffering spontaneous pain, allodynia, hyperalgesia, and other unpleasant symptoms. Decreased physical activity, increased fatigue, and mood and sleep problems may result.
Evidence Acquisition: A MEDLINE search was conducted, limiting searching to double-blind, randomized, controlled trials (1978 to present) of antiepileptic drugs (carbamazepine, gabapentin, pregabalin, topiramate, and lamotrigine) used in the treatment of chronic neuropathic pain.
Evidence Synthesis: The most important aspect of treatment is targeted at modification of the underlying disease. However, approaches to symptomatic pain control are essential and include multiple drug classes. Tricyclic antidepressants, including imipramine, nortriptyline, and amitriptyline, have been the mainstays of treatment, but anticholinergic effects, such as dry mouth, blurring of vision, constipation, orthostatic hypotension, and cardiac arrhythmias, as well as other adverse effects, often limit their use. Other treatments include capsaicin, clonidine, acupuncture, and electrical stimulation, suggesting that there is no single effective treatment. First-generation antiepileptic drugs have been shown to be effective in neuropathic pain. The evidence supporting the use of a new generation of antiepileptic drugs in painful diabetic neuropathy is reviewed.
This article has been cited by other articles:
![]() |
R. G. Smith Painful Diabetic Peripheral Neuropathy J Am Podiatr Med Assoc, September 1, 2007; 97(5): 394 - 401. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. T. Bloomgarden Diabetic Retinopathy and Diabetic Neuropathy Diabetes Care, March 1, 2007; 30(3): 760 - 765. [Full Text] [PDF] |
||||
![]() |
A. Turan, P. F. White, B. Karamanlioglu, and Z. Pamukcu Premedication with Gabapentin: The Effect on Tourniquet Pain and Quality of Intravenous Regional Anesthesia Anesth. Analg., January 1, 2007; 104(1): 97 - 101. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. L Page II and J. L Bainbridge Intractable Epistaxis Associated with Topiramate Administration Ann. Pharmacother., July 1, 2006; 40(7): 1462 - 1465. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Rowland, D. J. Elliot, J. A. Williams, P. I. Mackenzie, R. G. Dickinson, and J. O. Miners IN VITRO CHARACTERIZATION OF LAMOTRIGINE N2-GLUCURONIDATION AND THE LAMOTRIGINE-VALPROIC ACID INTERACTION Drug Metab. Dispos., June 1, 2006; 34(6): 1055 - 1062. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |